INVESTOR NOTICE: Lundin Law PC Announces Investigation Of Regulus Therapeutics Inc. And Advises Investors With Losses to Cont...
June 28 2016 - 2:56PM
Business Wire
Lundin Law PC announces it is investigating claims against
Regulus Therapeutics Inc. (“Regulus” or the “Company”) (Nasdaq:
RGLS) concerning possible violations of federal securities
laws.
To participate in this class action lawsuit, please contact
Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via
email at brian@lundinlawpc.com.
No class has been certified in the above action. Until a class
is certified, you are not considered represented by an attorney.
You may also choose to do nothing and be an absent class
member.
The investigation concerns whether the Company violated Sections
10(b) and 20(a) of the Securities Exchange Act of 1934.
Specifically, the investigation will focus on the Company’s June
27, 2016 announcement that it received verbal notice from the U.S.
Food and Drug Administration (“FDA”) that the FDA placed the
Company’s new investigational drug, for treatment of chronic
hepatitis C virus infection, on clinical hold after a second
serious case of jaundice was reported. Following this news, shares
of Regulus dropped sharply.
Lundin Law PC was created by Brian Lundin, a securities
litigator based in Los Angeles.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160628006519/en/
Lundin Law PCBrian Lundin, Esq.888-713-1033Facsimile:
888-713-1125brian@lundinlawpc.com
Regulus Therapeutics (NASDAQ:RGLS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Regulus Therapeutics (NASDAQ:RGLS)
Historical Stock Chart
From Jul 2023 to Jul 2024